Therapeutic Area

Renal Cell Carcinoma

Therapeutic area intelligence for Renal Cell Carcinoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Merck →

Assets

KEYTRUDA →

Recent signals(2)

ClinicalJune 17, 2026

Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC

The Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival and overall survival for the evaluated combination therapies.

RegulatoryJune 13, 2026

FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC

The FDA has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for adjuvant treatment in ccRCC patients, marking a significant advancement in therapy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Renal Cell Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.